Clavo Bernardino, Cánovas-Molina Angeles, Díaz-Garrido Juan A, Cañas Silvia, Ramallo-Fariña Yolanda, Laffite Horus, Federico Mario, Rodríguez-Abreu Delvys, Galván Saray, García-Lourve Carla, González-Beltrán Damián, Caramés Miguel A, Hernández-Fleta Jose L, Serrano-Aguilar Pedro, Rodríguez-Esparragón Francisco
Research Unit, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain.
Chronic Pain Unit, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain.
Front Psychol. 2023 Aug 4;14:1176204. doi: 10.3389/fpsyg.2023.1176204. eCollection 2023.
Patients with refractory symptoms of severe diseases frequently experience anxiety, depression, and an altered health-related quality of life (HRQOL). Some publications have described the beneficial effect of ozone therapy on several symptoms of this kind of patient. The aim of this study was to preliminarily evaluate, in patients treated because of refractory symptoms of cancer treatment and advanced nononcologic diseases, if ozone therapy has an additional impact on self-reported anxiety and depression.
Before and after ozone treatment, we assessed (i) anxiety and depression according to the Hospital Anxiety and Depression Scale (HADS); (ii) the HRQOL (according to the EQ-5D-5L questionnaire), which includes a dimension on anxiety and depression and a visual analog scale (VAS) measuring self-perceived general health.
Before ozone therapy, 56% of patients were on anxiolytic and/or antidepressant treatment. Before and after ozone therapy, the anxiety and depression HADS subscales (i) significantly correlated with the anxiety/depression dimension of the EQ-5D-5L questionnaire and (ii) inversely correlated with the health status as measured by the VAS. After ozone therapy, we found a significant improvement in anxiety and depression measured by both the (i) HADS subscales and (ii) EQ-5D-5L questionnaire.
The addition of ozone therapy for patients with refractory symptoms of cancer treatment and advanced chronic nononcologic diseases can decrease anxiety and depression severity levels. Additional, more focused studies are ongoing to provide the needed explanatory information for this finding.
患有严重疾病难治性症状的患者经常会出现焦虑、抑郁以及与健康相关的生活质量（HRQOL）改变。一些出版物描述了臭氧疗法对这类患者多种症状的有益效果。本研究的目的是在因癌症治疗难治性症状和晚期非肿瘤性疾病接受治疗的患者中，初步评估臭氧疗法对自我报告的焦虑和抑郁是否有额外影响。
在臭氧治疗前后，我们评估了：（i）根据医院焦虑抑郁量表（HADS）评估焦虑和抑郁；（ii）HRQOL（根据EQ-5D-5L问卷），其中包括焦虑和抑郁维度以及测量自我感知总体健康的视觉模拟量表（VAS）。
在臭氧治疗前，56%的患者正在接受抗焦虑和/或抗抑郁治疗。在臭氧治疗前后，焦虑和抑郁的HADS子量表：（i）与EQ-5D-5L问卷的焦虑/抑郁维度显著相关；（ii）与VAS测量的健康状况呈负相关。臭氧治疗后，我们发现通过（i）HADS子量表和（ii）EQ-5D-5L问卷测量的焦虑和抑郁有显著改善。
对于癌症治疗难治性症状和晚期慢性非肿瘤性疾病患者，增加臭氧疗法可降低焦虑和抑郁的严重程度。正在进行更多有针对性的研究，以提供这一发现所需的解释性信息。
